Conversation with The Cancer LetterFreeHealth Equity NCTN group chairs, experts: Diverse representation of minorities in clinical trials and drug development saves lives November 12, 2021Vol.47 No.42By Matthew Bin Han Ong
Conversation with The Cancer Letter FDA’s review of “dangling indications” continues beyond PD-1 and PD-L1 drugs October 15, 2021Vol.47 No.38By Paul Goldberg
Trials & Tribulations Converting Cox hazard ratios with Cox-TEL to improve interpretation of drug efficacy in checkpoint inhibitor trials September 10, 2021Vol.47 No.33By Yu Shyr
Free Pazdur expresses “profound concerns” about single-arm studies of PD-1/PD-L1 drugs; ODAC nixes retifanlimab for anal cancer June 25, 2021Vol.47 No.25By Paul Goldberg
Trials & Tribulations Annals of Unintended Consequences: How FDA regulations undermine the biosimilar marketplace and the BPCIA June 18, 2021Vol.47 No.24By Howard S. Hochster and Michael P. Kane
RIP MTD: FDA to require sponsors to determine optimal dosage before initiating pivotal trials in cancer June 11, 2021Vol.47 No.23By Paul Goldberg
Guest Editorial Optimize the dose: An optimal step forward for FDA June 11, 2021Vol.47 No.23By Mark J. Ratain, Garth W. Strohbehn, Ian F. Tannock and Allen S. Lichter
Conversation with The Cancer LetterFree We ask FDA to explain “dangling” accelerated approvals—and this week’s ODAC agenda April 30, 2021Vol.47 No.17By Paul Goldberg
Free FDA’s Critics Call for Full Integration of Oncology Center Under Biden’s Moonshot May 06, 2016Vol.42 No.18By Matthew Bin Han Ong
